Trial Profile
A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Lirametostat (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; First in man
- Sponsors Constellation Pharmaceuticals
- 15 Nov 2018 Status changed from active, no longer recruiting to completed, as reported in a Constellation Pharmaceuticals media release.
- 07 Mar 2018 Results presented at the 16th International Congress on Targeted Anticancer Therapies
- 02 Mar 2018 Status changed from recruiting to active, no longer recruiting.